UCB SA (UCB)-医療機器分野:企業M&A・提携分析

◆英語タイトル:UCB SA (UCB) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011958
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company’s key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn’s disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA (UCB) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
UCB SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
UCB SA, Medical Equipment Deals By Type, 2011 to YTD 2017 6
UCB SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
UCB SA, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
UCB SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
UCB SA, Medical Equipment, Deal Details 10
Partnerships 10
Partners HealthCare System and UCB Enter into Agreement 10
MC10 Enters into Agreement with UCB 11
Evogen Enters into Agreement with UCB 12
MC10 Enters into Co-Development Agreement with UCB 13
Allium Medical Solutions Enters Into Distribution Agreement With Meizler UCB Biopharma For Urological Stents 14
OTR3 Enters Into Distribution Agreement With UCB For Cacipliq20 15
King’s College London Enters Into Licensing Agreement with UCB 16
Acquisition 17
UCB Acquires 51% Stake In Meizler Biopharma 17
UCB SA – Key Competitors 18
UCB SA – Key Employees 19
UCB SA – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Joint Venture 23
Recent Developments 24
Strategy And Business Planning 24
Apr 04, 2016: Heptares Joins Pharma Consortium Applying State of the Art Cryo-Electron Microscopy to Advance Structure Based Drug Discovery 24
Financial Announcements 25
Oct 20, 2017: UCB First Nine Months Interim Report 2017: Strong 9 months performance allows for increase of 2017 financial outlook 25
Jul 27, 2017: UCB with a strong first half year 2017 – giving rise to the financial outlook for 2017 27
Apr 24, 2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017 30
Jul 27, 2016: UCB continues to deliver on its growth strategy 31
Apr 25, 2016: UCB First Three Months Interim Report 2016 32
Feb 26, 2016: UCB with progress on its growth path delivering value to patients and shareholders 33
Corporate Communications 35
Mar 24, 2017: UCB General Meeting on 27 April 2017 35
Dec 15, 2016: New appointments on UCB’s Board of Directors 36
Mar 25, 2016: Nominations for new members of UCB’s Board of Directors 37
Jan 15, 2016: UCB’s Executive Committee welcomes a new member 38
Other Significant Developments 39
Apr 26, 2017: UCB Selects Medidata Clinical Cloud to Support Patient-Centric Drug Development 39
Jan 05, 2017: MC10 and UCB Complete Landmark Pharmaceutical / Technology Collaboration Evaluating Patient Monitoring in Parkinson’s 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
UCB SA, Medical Equipment, Key Facts, 2016 2
UCB SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
UCB SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
UCB SA, Medical Equipment Deals By Type, 2011 to YTD 2017 6
UCB SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
UCB SA, Deals By Market, 2011 to YTD 2017 8
UCB SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Partners HealthCare System and UCB Enter into Agreement 10
MC10 Enters into Agreement with UCB 11
Evogen Enters into Agreement with UCB 12
MC10 Enters into Co-Development Agreement with UCB 13
Allium Medical Solutions Enters Into Distribution Agreement With Meizler UCB Biopharma For Urological Stents 14
OTR3 Enters Into Distribution Agreement With UCB For Cacipliq20 15
King’s College London Enters Into Licensing Agreement with UCB 16
UCB Acquires 51% Stake In Meizler Biopharma 17
UCB SA, Key Competitors 18
UCB SA, Key Employees 19
UCB SA, Subsidiaries 20
UCB SA, Joint Venture 23

★海外企業調査レポート[UCB SA (UCB)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kyocera Corporation (6971):電力:M&Aディール及び事業提携情報
    Summary Kyocera Corporation (Kyocera) is a provider of electronic equipment and components. The company’s portfolio includes semiconductor parts, ceramic components, mobile phones, electronic devices, telecommunications and information equipment, and others. These products find application in variou …
  • AptarGroup Inc:企業の戦略・SWOT・財務情報
    AptarGroup Inc - Strategy, SWOT and Corporate Finance Report Summary AptarGroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Hikma Pharmaceuticals PLC:戦略・SWOT・企業財務分析
    Hikma Pharmaceuticals PLC - Strategy, SWOT and Corporate Finance Report Summary Hikma Pharmaceuticals PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Medica Corp:企業の製品パイプライン分析2018
    Summary Medica Corp (Medica) is a medical device company that manufactures and markets in-vitro diagnostic blood testing analyzers. The company’s products comprise clinical chemistry analyzers, electrolyte analyzers, blood gas analyzers, and hematology analyzers, and OEM ISE modules. Medica’s produc …
  • NanoPass Technologies Ltd:医療機器:M&Aディール及び事業提携情報
    Summary NanoPass Technologies Ltd (NanoPass) is a medical device company that develops and commercializes intradermal delivery solutions for vaccines and drugs. The company's product include MicronJet600 needle, a single use microneedles based device for intradermal delivery. Its micronjet microneed …
  • OSI Maritime Systems:企業の戦略・SWOT・財務情報
    OSI Maritime Systems - Strategy, SWOT and Corporate Finance Report Summary OSI Maritime Systems - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • ZAD Bulstrad Vienna Insurance Group:企業の戦略・SWOT・財務分析
    ZAD Bulstrad Vienna Insurance Group - Strategy, SWOT and Corporate Finance Report Summary ZAD Bulstrad Vienna Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Ulster Bank Ireland DAC:企業の戦略的SWOT分析
    Ulster Bank Ireland DAC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • KDDI Corporation:企業の戦略・SWOT・財務情報
    KDDI Corporation - Strategy, SWOT and Corporate Finance Report Summary KDDI Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • GEDI Gruppo Editoriale SpA (GEDI):企業の財務・戦略的SWOT分析
    GEDI Gruppo Editoriale SpA (GEDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Peloton Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Peloton Therapeutics Inc (Peloton) is a clinical-stage pharmaceutical company that develops oral medicines and novel therapies for oncology. Its portfolio of pipeline products includes PT2977, PT2567 and PT2385. The company develops its products for the treatment of pulmonary arterial hypert …
  • Cleanaway Waste Management Ltd (CWY):企業の戦略的SWOT分析
    Cleanaway Waste Management Ltd (CWY) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Sumitomo Chemical Co., Ltd.:企業の戦略・SWOT・財務分析
    Sumitomo Chemical Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Chemical Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Mudman Public Company Limited (MM):企業の財務・戦略的SWOT分析
    Mudman Public Company Limited (MM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Warrnambool Cheese and Butter Factory Company Holdings Limited:企業の戦略・SWOT・財務情報
    Warrnambool Cheese and Butter Factory Company Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Warrnambool Cheese and Butter Factory Company Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report cov …
  • Grasim Industries Limited:企業の戦略・SWOT・財務分析
    Grasim Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Grasim Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • HearMeOut Ltd (HMO):企業の財務・戦略的SWOT分析
    HearMeOut Ltd (HMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Labrador Iron Mines Holdings Limited:企業の戦略・SWOT・財務情報
    Labrador Iron Mines Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Labrador Iron Mines Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • ASOS Plc:企業の戦略・SWOT・財務情報
    ASOS Plc - Strategy, SWOT and Corporate Finance Report Summary ASOS Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Bonanza Creek Energy Inc (BCEI):石油・ガス:M&Aディール及び事業提携情報
    Summary Bonanza Creek Energy Inc (Bonanza Creek) is an oil and gas company that acquires, explores, develops and produces onshore oil and liquid-rich natural gas assets. The company employs hydraulic fracturing for oil and natural gas exploration, and measurement while drilling technology or borehol …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆